

TG THERAPEUTICS, INC.  
Form 8-K  
May 10, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **May 10, 2016**

**TG Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

**001-32639**

**36-3898269**

(State or Other Jurisdiction (Commission File Number)

(IRS Employer Identification No.)

of Incorporation)

**2 Gansevoort Street, 9<sup>th</sup> Floor**

**New York, New York 10014**

(Address of Principal Executive Offices)

**(212) 554-4484**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..                   Written communications pursuant to Rule 425 under the Securities Act.
- ..                   Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- ..                   Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- ..                   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 2.02. Results of Operations and Financial Condition.**

On May 10, 2016, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the first quarter ended March 31, 2016. TG also announced that on Tuesday, May 10, 2016 at 4:30pm ET, TG would host an investor conference call during which the Company would provide a brief overview of its first quarter financial results and provide a business outlook for the remainder of 2016. A copy of such press release is being furnished as Exhibit 99.1.

**Item 9.01 Financial Statements And Exhibits.**

(d)Exhibits.

99.1 Press release issued by TG Therapeutics, Inc., dated May 10, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**TG Therapeutics, Inc.**  
(Registrant)

By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer

Date: May 10, 2016

- 3 -

INDEX TO EXHIBITS

<b>Exhibit</b>	<b><u>Description</u></b>
<b><u>Number</u></b>	

99.1	Press release issued by TG Therapeutics, Inc., dated May 10, 2016.
------	--

- 4 -